Okajima et al. reported the administration of nimesulide and piroxicam as selective COX-2 inhibitor could reduce remarkable lowering of tumorigenesis rate in the BT using rat model which superficial BT initiating the tumor by administering the N-butyl-N-nitrosoamine.26 Okamoto et al. reported etodolac (selective COX-2 inhibitor) exhibited anti-tumor activity and induced E-cadherin expression in BT cells and might be useful for the clinical treatment and prevention of BT, especially in poorly differentiated bladder cancer with high COX-2 and low E-cadherin expression.27 Here, CDH1 is linked to urinary bladder carcinoma.